Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection.

Paul FeuerstadtSimon J HongLawrence J Brandt

Published in: Digestive diseases and sciences (2019)

Patients with cirrhosis who are on chronic rifaximin have decreased rates of CDI compared with those not on this therapy. Despite its risk for promoting resistance, chronic rifaximin use may have a beneficial effect in preventing CDI in patients with cirrhosis.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
irritable bowel syndrome
chronic kidney disease
peritoneal dialysis
stem cells
replacement therapy